Precision medicine is a technique for tailoring remedies based on people’s genetic makeup, lifestyle, and environment. These targeted interventions can fight diseases such as cancer, as well as neurological and metabolic diseases. The global market price of the precision medicine industry, which encompasses many companies, surpassed $70 billion last year and is expected to reach $175 billion in the next seven years.
Here are seven biopharmaceutical corporations that could potentially contribute to this increase in the market price of precision medicine in the coming years as they bring their clinical applicants to market soon.
More than 50 million people currently live with dementia. To treat dementia and diseases that affect cognitive function, various biotechnology companies are seeking to create safe and effective medications. Clinical-stage company AC Immune, founded in Switzerland, has an attractive product line in precision medicine. which aims to combat neurodegenerative diseases. This includes measures to diagnose, treat and prevent cognitive decline due to neurodegeneration.
The company’s PI-2620 Tau-PET tracer is a diagnostic tool that is currently in Phase 3 studies. It is designed to bind to the tau protein, which is linked to the progression of Alzheimer’s disease. The multibillion-dollar company has many applicants in phase 2 studies. This includes the Abeta vaccine, which can generate antibodies that target misfolded beta-amyloid to prevent buildup and slow the formation of amyloid plaques, a hallmark of Alzheimer’s disease. A trial is also underway to test the vaccine candidate in other people with Down syndrome. syndrome, who are at risk of developing Alzheimer’s disease. The results of the trial are expected to be published next year.
Moreover, AC Immune’s monoclonal antibody crenezumab, which also targets misfolded Abeta, is being examined in a prevention trial in Colombia.
The biotechnology company is also involved in the treatment of Parkinson’s disease, for which it has developed a vaccine based on alpha synuclein that is recently being studied in the clinic. Alpha synuclein is a protein linked to Parkinson’s disease.
And that’s not all. The company has some preclinical applicants who also aim to combat neurodegenerative diseases. These include diagnostic biomarkers, biologic drug applicants, and small molecules.
Alto Neuroscience, the California-based precision medicine company, secured $45 million last month in a Series C investment round, which it will use for the clinical progression of its central nerve formula (CNS) candidates.
This includes its three drug candidates for depression and post-traumatic stress disorder (PTSD), which are all being evaluated in phase 2 trials. Each of these drugs is designed to target brain processes that improve three different functions – cognition, emotion and regulation, sleep and activity.
Now, its candidate ALTO-300 has reaped promising results, as it “led to a significantly greater improvement in depression symptoms in a biomarker-characterized patient population,” according to a press release released last week. The study lasted for eight weeks, where potential predictive biomarkers were used to test the efficacy and safety of the drug. It was also found that more biomarker-characterized patients achieved a clinical response rather than patients without the biomarker.
To achieve this, biotechnology has created a biomarker platform powered by synthetic intelligence. Its precision psychiatry platform aims to stimulate biomarkers of drug progression, a potentially effective approach to assessing brain function.
Based in the California biotechnology hub, Biomea Fusion is immersed in the discovery and advancement of small molecules to treat others with genetically explained cancers and metabolic diseases. The company’s small covalent molecules are designed to form a bond with a target protein.
Its drug candidate BMF-219 is currently being studied in type 2 diabetes. The candidate also recently obtained approval from the US Food and Drug Administration (FDA) for its investigational new drug application (IND) for diabetes. type 1 diabetes, allowing it to move into phase 2 trials as well. The candidate is a menin inhibitor capable of regenerating insulin-producing beta cells. The safety, efficacy and durability of the candidate will be evaluated in patients with 1 diabetes.
But that’s not all that BMF-219 is committed to treating. The candidate is being tested in a number of cancer indications like leukemia, lymphoma, myeloma, and non-small cell lung cancer, among others, all of which are in the phase 1 stage. It works by blocking the interaction of the protein menin, and restricts activity from cancer-driving genes.
BMF-219 showed evidence of clinical activity and was able to generate complete responses with minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML), based on effects presented at ASH 2023.
Part of the biotech scene in Singapore, the company Engine Biosciences is focused on drug development programs based on precision medicine. It raised $27 million in October, for advancing its oncology programs that are in their discovery phase.
These come with applicants for treatment of a variety of cancers, including ovarian, liver, colorectal, prostate, and breast, among others. One of their applicants targets a protein kinase called PKMYT1, which contributes to tumor progression.
The company also has more than 15 biomarker systems that are currently clinical. In addition to precision oncology, the company has also learned curative targets in the field of neurology.
The company’s NetMAPPR platform mines through the database that combines machine learning and biology to identify potential synthetic lethal connections that are then progressed through the pipeline. Engine Biosciences has also curated a library of gene connections with the help of its platform.
A pipeline centered around rare disease therapeutics, ReCode Therapeutics has developed mRNA-based treatments to tackle primary ciliary dyskinesia and cystic fibrosis.
Primary ciliary dyskinesia is a condition caused by genetic mutations, in which the hair cilia found in the lungs, nose, and ears are affected, leading to mucus buildup and infection due to the inability of the altered cilia to remove pollutants. which targets the DNAI1 gene, aims to treat the disease and is recently in phase 1/2 trials. It also has two applicants in the discovery phase who are targeting the PCD 2 gene and the PCD 3 gene to treat ciliary dyskinesia number one.
Their remedy for cystic fibrosis is an investigational cure based on inhaled disease-modifying mRNA that targets a fraction of the patient population who have nonsense mutations and don’t respond to drugs like CFTR modulators, which are regularly given to treat disease.
Recently, the precision medicine company closed a $260 million Series B round, with which it will continue to expand its candidates, as well as its Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform. With the SORT LNP platform, the company is expanding its portfolio of gene correction therapies. LNP SORT is helping to package medications and deliver them.
U.S.-based Scorpion Therapeutics is attempting to find ways to selectively target and strike against cancer. Since its inception in 2020, the company has been committed to a precision medicine approach to treat cancer.
By identifying the explicit points of cancer in patients, their goal is to decide on the treatment strategy that works most productively for each individual. Using computational biology techniques and genomic databases of human tumors, it creates small molecules expressed as a target. Scorpion Therapeutics also uses equipment such as CRISPR to identify drug targets that have not been effectively addressed before.
The company has two applicants in 1 studies. STX-478 is an oral PI3Kα inhibitor, which is being developed to treat breast, gynecological, and head and neck cancers with the PI3Kα mutation. The candidate has expressed antitumor activity in preclinical studies.
The other candidate in phase 1 is STX-721. Su purpose is to selectively target exon 20 insertion mutations in EGFR, a non-small mobile lung cancer oncogene. Previously, in xenograft models, the candidate showed promise in the potential cancer remedy. But we haven’t yet figured out how phase 1 of the trial will play out.
American company SpringWorks Therapeutics specializes in targeted oncology. Its gamma secretase inhibitor called nirogacestat has received orphan drug designation, fast track and breakthrough therapy designations from the FDA for treating adult desmoid tumors.
Desmoid tumors are rare, noncancerous tumors that appear in connective tissue. Nirogacestat works by inhibiting gamma secretase, an enzyme that helps activate a signaling protein called Notch. Since these proteins are ideal for stimulating the growth of desmoid tumors because they are provided in high amounts in tumors, suppressing the production of Notch protein can prevent tumor expansion. The candidate is also being studied as monotherapy in phase 2 trials in pediatric desmoid tumors, as well as tumors in ovarian granulosa cells, a rare type of ovarian cancer for the U. S. government. It is also being evaluated in combination with several other treatments for the treatment of relapsed or refractory multiple myeloma.
As part of biotech’s precision oncology strategy to study investigational drugs to treat metastatic cancers explained through biomarkers, the company is also developing a MEK inhibitor, mirdametinib, to treat cancers, adding NF1-associated plexiform neurofibromas, for which it is in Phase 2b. Lawsuit. It has also partnered with global pharmaceutical company BeiGene to treat fake tumors with mirdametinib in combination with lifirafenib, an RAF inhibitor. In addition, biotechnology is developing other inhibitors. The company closed a public offering worth more than $300 million last week.
Among the big leagues of biopharma, Novartis is one of the multinational corporations investing in precision medicine. The company has created next-generation sequencing assays in collaboration with molecular diagnostics company Genoptix. The diagnostic test identifies express mutations provided in patients, allowing the drug to be chosen as the most productive based on the patient’s genetic makeup.
Pfizer is another multinational company that also leverages precision medicine for drug discovery. This includes biomarker studies and imaging tools. Similarly, AstraZeneca focuses on treating asthma and metabolic disorders using precision medicine. It does this by identifying drug targets and biomarkers, and developing diagnostic tests that can help consulting patients through treatment options.
Other competition comes from Amgen, Roche, Bristol Myers Squibb and even BioNTech, which recently partnered with the UK government to deliver personalized cancer treatments to up to 10,000 patients by the end of 2030. This will allow BioNTech’s clinical systems to Personalized cancer immunotreatments with mRNA advance further. The company is finishing up designing and publishing clinical trials for its precision medicine applicants in the near future.
“*” Required Fields